Top Markets
Coin of the day
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc.

INTI
Rang in aandelen #30838
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida,... Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Aandeelprijs
$0.089
Laatst gesynchroniseerd: 2026-08-17
Marktkapitalisatie
$15.36M
Verandering (1 dag)
50.59%
Verandering (1 jaar)
111.85%
Land
US
Handel Inhibitor Therapeutics, Inc. (INTI)

Categorie

Prijs INTI met de marktkapitalisatie van B
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
INTI
$0.089
Marktkapitalisatie van Inhibitor Therapeutics, Inc.(INTI)
Marktkapitalisatie: $15.36M
Vanaf August 2026 heeft Inhibitor Therapeutics, Inc. een marktkapitalisatie van $15.36M. Dit maakt Inhibitor Therapeutics, Inc. volgens onze gegevens het 30838th meest waardevolle bedrijf ter wereld op basis van marktkapitalisatie. De marktkapitalisatie is de totale marktwaarde van alle uitstaande aandelen van een beursgenoteerd bedrijf en wordt vaak gebruikt om de waarde van een bedrijf te meten.
Marktkapitalisatiegeschiedenis van Inhibitor Therapeutics, Inc. van 2003 tot 2026
INTI vergeleken met de top 5 populairste stocks
Prijs voor INTI Aandeel B Marktkapitalisatie van B uitslagen
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
$30,749.66 $15.36M
$5.307T +34,550,085.07%
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
$26,369.80 $15.36M
$4.551T +29,628,891.27%
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
$24,072.99 $15.36M
$4.154T +27,048,208.47%
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
$20,794.30 $15.36M
$3.589T +23,364,277.97%
Inhibitor Therapeutics, Inc. Inhibitor Therapeutics, Inc.
$16,206.69 $15.36M
$2.797T +18,209,663.87%